Xeris Biopharma Holdings

ISIN US98422E1038

 | 

WKN A3C4ZC

Market cap (in EUR)
823 m
Country
United States
Sector
Healthcare
Dividend yield
0.00%
 

Overview

Description

Xeris Biopharma Holdings, Inc. is a biopharmaceutical company, which engages in developing and commercializing products across a range of therapies. The company has three commercial products: Gvoke, Keveyis, and Recorlev. Gvoke is ready-to-use liquid glucagon for the treatment of severe hypoglycemia. Keveyis is the therapy approved in the United States to treat hyperkalemic, hypokalemic, and related variants of primary periodic paralysis (PPP). Recorlev is a cortisol synthesis inhibitor approved for the treatment of endogenous hypercortisolemia in adult patients with Cushing’s syndrome. Its product also includes Ogluo which is used for the treatment of severe hypoglycemia in adults, adolescents, and children aged 2 years and over with diabetes mellitus. The company was founded by Steven Prestrelski in 2005 and is headquartered in Chicago, IL.
Show more Show less
Healthcare Biopharmaceuticals System-Specific Biopharmaceuticals United States

Financials

Key metrics

Market capitalisation, EUR 823 m
EPS, EUR -0.01
P/B ratio 66.3
P/E ratio 1,706.2
Dividend yield 0.00%

Income statement (2025)

Revenue, EUR 259 m
Net income, EUR 0 m
Profit margin 0.19%

What ETF is Xeris Biopharma Holdings in?

There is 1 ETF which contains Xeris Biopharma Holdings.
ETF Weight Investment focus Fund size (in m EUR)
iShares Nasdaq US Biotechnology UCITS ETF USD (Dist) 0.09%
Equity
United States
Health Care
Biotech
47
— Data provided by Trackinsight, etfinfo, Xignite Inc., gettex, FactSet and justETF GmbH.

Quotes are either real-time (gettex) or 15 minutes delayed stock exchange quotes or NAVs (daily published by the fund provider). By default, ETF returns include dividend payments (if applicable). There is no warranty for completeness, accuracy and correctness for the displayed information.